Home

esilio Principe spina puma investor relations Serrato predire proteggere

PUMA® - Financial News
PUMA® - Financial News

PUMA® - Corporate Governance
PUMA® - Corporate Governance

PUMA® - PUMA Investor Relations
PUMA® - PUMA Investor Relations

PUMA SE (@PUMAGroup) / Twitter
PUMA SE (@PUMAGroup) / Twitter

PUMA® - PUMA Investor Relations
PUMA® - PUMA Investor Relations

PUMA® - Financial News
PUMA® - Financial News

PUMA® - Annual General Meeting
PUMA® - Annual General Meeting

PUMA® - Financial News
PUMA® - Financial News

PUMA® - PUMA Investor Relations
PUMA® - PUMA Investor Relations

PUMA IGNITE Digital Campaign on Behance
PUMA IGNITE Digital Campaign on Behance

PUMA® - PUMA releases preliminary results for the fourth quarter and  financial year 2021
PUMA® - PUMA releases preliminary results for the fourth quarter and financial year 2021

PUMA® - Contact
PUMA® - Contact

PUMA® - Annual General Meeting
PUMA® - Annual General Meeting

Le azioni Puma torneranno a ruggire? - Word2Invest
Le azioni Puma torneranno a ruggire? - Word2Invest

PUMA® - PUMA Investor Relations
PUMA® - PUMA Investor Relations

PUMA® - Annual General Meeting
PUMA® - Annual General Meeting

PUMA Announces Exclusive Formula 1 Partnership | Hypebeast
PUMA Announces Exclusive Formula 1 Partnership | Hypebeast

PUMA® - Financial Calendar
PUMA® - Financial Calendar

Puma Energy Zambia Plc (PUMA.zm)
Puma Energy Zambia Plc (PUMA.zm)

PUMA® - Corporate Governance
PUMA® - Corporate Governance

PUMA® - Annual General Meeting
PUMA® - Annual General Meeting

Le azioni Puma torneranno a ruggire? - Word2Invest
Le azioni Puma torneranno a ruggire? - Word2Invest

PUMA® - Share
PUMA® - Share

PUMA® - PUMA achieves another record Quarter in Sales and EBIT despite  Geopolitical Tensions and Lockdown Measures
PUMA® - PUMA achieves another record Quarter in Sales and EBIT despite Geopolitical Tensions and Lockdown Measures

Puma Biotechnology Announces Exclusive License Agreement with Takeda for  the Development and Commercialization of Alisertib, an Investigational  Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire

PUMA® - Investor Presentations
PUMA® - Investor Presentations